FAIRFIELD, N.J.--(BUSINESS WIRE)--The site-directed bone growth (SDBG) technology currently being developed by Unigene Laboratories, Inc. (OTCBB: UGNE) in conjunction with Yale University may have the potential to provide clinicians with new techniques to target bone growth at the site of a fracture or at sites that are highly susceptible to fracture. This promising early-stage technology is currently being studied in animals. Unigene has identified several possible applications of this technology, each with substantial commercial potential.
